281 related articles for article (PubMed ID: 30985373)
1. Age and the risks of high-efficacy disease modifying drugs in multiple sclerosis.
Schweitzer F; Laurent S; Fink GR; Barnett MH; Reddel S; Hartung HP; Warnke C
Curr Opin Neurol; 2019 Jun; 32(3):305-312. PubMed ID: 30985373
[TBL] [Abstract][Full Text] [Related]
2. Classifying PML risk with disease modifying therapies.
Berger JR
Mult Scler Relat Disord; 2017 Feb; 12():59-63. PubMed ID: 28283109
[TBL] [Abstract][Full Text] [Related]
3. Aging and lymphocyte changes by immunomodulatory therapies impact PML risk in multiple sclerosis patients.
Mills EA; Mao-Draayer Y
Mult Scler; 2018 Jul; 24(8):1014-1022. PubMed ID: 29774781
[TBL] [Abstract][Full Text] [Related]
4. Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies.
Wingerchuk DM; Carter JL
Mayo Clin Proc; 2014 Feb; 89(2):225-40. PubMed ID: 24485135
[TBL] [Abstract][Full Text] [Related]
5. Switching patients at high risk of PML from natalizumab to another disease-modifying therapy.
Giovannoni G; Marta M; Davis A; Turner B; Gnanapavan S; Schmierer K
Pract Neurol; 2016 Oct; 16(5):389-93. PubMed ID: 27114560
[TBL] [Abstract][Full Text] [Related]
6. Infection risk in patients on multiple sclerosis therapeutics.
Williamson EM; Berger JR
CNS Drugs; 2015 Mar; 29(3):229-44. PubMed ID: 25761739
[TBL] [Abstract][Full Text] [Related]
7. Influence of physicians' risk perception on switching treatments between high- efficacy and non-high-efficacy disease‑modifying therapies in multiple sclerosis.
Seifer G; Arun T; Capela C; Laureys G; Jones E; Dominguez-Castro P; Sanchez-de la Rosa R; Hiltl S; Iaffaldano P
Mult Scler Relat Disord; 2023 Aug; 76():104770. PubMed ID: 37307690
[TBL] [Abstract][Full Text] [Related]
8. Drug-induced progressive multifocal leukoencephalopathy in multiple sclerosis: European regulators' perspective.
Anton R; Haas M; Arlett P; Weise M; Balabanov P; Mazzaglia G; Prieto L; Keller-Stanislawski B; Raine J
Clin Pharmacol Ther; 2017 Aug; 102(2):283-289. PubMed ID: 28001298
[TBL] [Abstract][Full Text] [Related]
9. Update on monitoring and adverse effects of approved second-generation disease-modifying therapies in relapsing forms of multiple sclerosis.
Dubey D; Cano CA; Stüve O
Curr Opin Neurol; 2016 Jun; 29(3):278-85. PubMed ID: 27027553
[TBL] [Abstract][Full Text] [Related]
10. Prevention and management of adverse effects of disease modifying treatments in multiple sclerosis.
Moiola L; Rommer PS; Zettl UK
Curr Opin Neurol; 2020 Jun; 33(3):286-294. PubMed ID: 32374570
[TBL] [Abstract][Full Text] [Related]
11. As time goes by: Treatment challenges in elderly people with multiple sclerosis.
Gelibter S; Saraceno L; Pirro F; Susani EL; Protti A
J Neuroimmunol; 2024 Jun; 391():578368. PubMed ID: 38761652
[TBL] [Abstract][Full Text] [Related]
12. A survey of risk tolerance to multiple sclerosis therapies.
Fox RJ; Cosenza C; Cripps L; Ford P; Mercer M; Natarajan S; Salter A; Tyry T; Cofield SS
Neurology; 2019 Apr; 92(14):e1634-e1642. PubMed ID: 30867272
[TBL] [Abstract][Full Text] [Related]
13. Update on disease-modifying therapies for multiple sclerosis.
Vargas DL; Tyor WR
J Investig Med; 2017 Jun; 65(5):883-891. PubMed ID: 28130412
[TBL] [Abstract][Full Text] [Related]
14. Benefit-risk perception of natalizumab therapy in neurologists and a large cohort of multiple sclerosis patients.
Heesen C; Kleiter I; Meuth SG; Krämer J; Kasper J; Köpke S; Gaissmaier W
J Neurol Sci; 2017 May; 376():181-190. PubMed ID: 28431609
[TBL] [Abstract][Full Text] [Related]
15. Use of natalizumab in multiple sclerosis: current perspectives.
Gandhi S; Jakimovski D; Ahmed R; Hojnacki D; Kolb C; Weinstock-Guttman B; Zivadinov R
Expert Opin Biol Ther; 2016 Sep; 16(9):1151-62. PubMed ID: 27413840
[TBL] [Abstract][Full Text] [Related]
16. Infections in Patients Receiving Multiple Sclerosis Disease-Modifying Therapies.
Grebenciucova E; Pruitt A
Curr Neurol Neurosci Rep; 2017 Sep; 17(11):88. PubMed ID: 28940162
[TBL] [Abstract][Full Text] [Related]
17. Multiple sclerosis, natalizumab, and PML: helping patients decide.
Rudick RA
Cleve Clin J Med; 2011 Nov; 78 Suppl 2():S18-23. PubMed ID: 22123928
[TBL] [Abstract][Full Text] [Related]
18. Natalizumab for multiple sclerosis: appraising risk versus benefit, a seemingly demanding tango.
Gupta S; Weinstock-Guttman B
Expert Opin Biol Ther; 2014 Jan; 14(1):115-26. PubMed ID: 24289270
[TBL] [Abstract][Full Text] [Related]
19. Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases.
Clifford DB; De Luca A; Simpson DM; Arendt G; Giovannoni G; Nath A
Lancet Neurol; 2010 Apr; 9(4):438-46. PubMed ID: 20298967
[TBL] [Abstract][Full Text] [Related]
20. A decade of natalizumab and PML: Has there been a tacit transfer of risk acceptance?
Clifford DB; Yousry TA; Major EO
Mult Scler; 2017 Jun; 23(7):934-936. PubMed ID: 27679459
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
